Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — September 2024

Genmab — September 2024

Planlagt Fastgjort Låst Flyttet Genmab
1.1k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #32

    'Genmab stock stabilized but faces uncertainties ahead' says Morgan Stanley https://za.investing.com/news/company-news/genmab-stock-stabilized-but-faces-uncertainties-ahead-says-morgan-stanley-93CH-3316303

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #33

      Lymphoma Hub
      @lymphomahub
      CONGRESS | POSTER | #SOHO2024 | Daniel Kerr presents first results from the phase Ib/II EPCORE NHL-5 study investigating subcutaneous epcoritamab + pola-R-CHP as 1L treatment for #DLBCL (N=37). The ORR was 100% with CR 89%, demonstrating that epcoritamab can be combined with 1L SoC for DLBCL. https://x.com/lymphomahub/status/1831287376901013605/photo/1

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #34

        difficult to read, but i don't need much more than ORR of 100% , CR 89% and no new safety signals

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #35

          poster on glofitamab monotherapy in pts with R/R #DLBCL https://x.com/lymphomahub/status/1831291358440464845

          1 Reply Last reply
          0
          • BulderB Offline
            BulderB Offline
            Bulder
            wrote on sidst redigeret af
            #36

            But probably not enough pts for a filing.

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #37

              good point. How many do you think they need to go for a filing / Ph3 anyway? We don't know yet if these are all the patients that will be recruited in this arm, this is only first data, there may be more coming?

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #38

                Lymphoma Hub
                @lymphomahub
                CONGRESS | POSTER | #SOHO2024 | Yasmin Karimi
                @Yhkarimi
                presents extended follow-up data beyond 2.5 years from the pivotal expansion cohort of the phase II EPCORE NHL-1 study of epcoritamab monotherapy in R/R #DLBCL (N=157). Of pts with a CR (n=65) 54% remained in CR at 30 months, with 69% PFS and 85% OS rates. https://x.com/lymphomahub/status/1831299262438641727

                1 Reply Last reply
                0
                • BulderB Offline
                  BulderB Offline
                  Bulder
                  wrote on sidst redigeret af
                  #39

                  Maybe Winkel will talk about it tonight.

                  1 Reply Last reply
                  0
                  • S Offline
                    S Offline
                    Sukkeralf
                    wrote on sidst redigeret af
                    #40

                    maybe good for off-label sales

                    1 Reply Last reply
                    0
                    • R Offline
                      R Offline
                      Raun
                      wrote on sidst redigeret af
                      #41

                      Vil nogen være sød og forklare mig. - Hvad hensigten kan være, når Morgan Stanley har brug for at gentage deres nedjustering af Genmab, bare ca. 14 dage efter nedjusteringen?

                      1 Reply Last reply
                      0
                      • G Offline
                        G Offline
                        gdn55
                        wrote on sidst redigeret af
                        #42

                        For at tjene penge, der er mit bedste bud

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #43

                          The innovaTV 301 Trial for Patients with Cervical Cancer https://www.primrmed.com/cancer-education/the-innovatv-301-trial-for-patients-with-cervical-cancer

                          1 Reply Last reply
                          0
                          • S Offline
                            S Offline
                            Sukkeralf
                            wrote on sidst redigeret af
                            #44

                            Jan var da i særdeles godt humør i dag 🙂

                            1 Reply Last reply
                            0
                            • BulderB Offline
                              BulderB Offline
                              Bulder
                              wrote on sidst redigeret af
                              #45

                              Hørte det ikke. Noget interessant?

                              1 Reply Last reply
                              0
                              • K Offline
                                K Offline
                                kkjoel
                                wrote on sidst redigeret af
                                #46

                                Han forklarede bl.a. om Superdaras virkningsmekanisme og gentog at den er super potent... og at han nok skulle hjælpe JNJ med at forstå det hvis de ikke selv kunne se det 😉

                                1 Reply Last reply
                                0
                                • K Offline
                                  K Offline
                                  kkjoel
                                  wrote on sidst redigeret af
                                  #47

                                  Men der var selvfølgelig meget gentagelse.. og som Sukker siger var han i trashtalk-topform 🙂

                                  1 Reply Last reply
                                  0
                                  • K Offline
                                    K Offline
                                    kkjoel
                                    wrote on sidst redigeret af
                                    #48

                                    Orker ikke - og kan ikke huske udenad - alt hvad han roste og fremhævede.. man må hellere læse transscriptet, som vel komme i morgen.

                                    1 Reply Last reply
                                    0
                                    • K Offline
                                      K Offline
                                      kkjoel
                                      wrote on sidst redigeret af
                                      #49

                                      Jo.... han fremhøvede osse hvor meget han stadig er glad for 1046, som BioTech optede ud af for nylig. Han var overbevist om det skyldtes at de to andre lignende stoffer (med samme cancermål) var ejet 100% af dem.. og at det var af afgørende betydning for Biotechs valg.

                                      1 Reply Last reply
                                      0
                                      • P Offline
                                        P Offline
                                        peter12
                                        wrote on sidst redigeret af
                                        #50

                                        De snakkede meget om Rina-S som de ville brede ud til flere indikationer snart (weeks). Der ville komme flere data på ESMO

                                        1 Reply Last reply
                                        0
                                        • K Offline
                                          K Offline
                                          kkjoel
                                          wrote on sidst redigeret af
                                          #51

                                          Mener faktisk han fik fyret en slytbredside af der: han sagde at han jublede, da de offentliggjorde beslutningen.. og at aktiemarkedets reaktion dagen efter var en lidt anden. Det var altså bare übertrash!!

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper